Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCVAC/LuCa

Next Previous
Search
Drug Profile

DCVAC/LuCa

Alternative Names: Dendritic cell vaccine/Lung cancer - Sotio

Latest Information Update: 20 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SOTIO
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 01 Nov 2021 Sotio completes a phase I/II trial in Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease) in Slovakia (SC) (NCT02470468)
  • 03 Jun 2019 Updated adverse events and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 03 Jun 2018 Efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top